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Protein arginine methylationCellular nucleic acid binding protein (CNBP) contains seven zinc ﬁnger (ZF) repeats and an arginine
and glycine (RG) rich sequence between the ﬁrst and the second ZF. CNBP interacts with protein
arginine methyltransferase PRMT1. Full-length but not RG-deleted or mutated CNBP can be methyl-
ated. Treatment with a methylation inhibitor AdOx reduced CNBP methylation, but did not affect
the concentrated nuclear localization of CNBP. Nevertheless, arginine methylation of CNBP appeared
to interfere with its RNA binding activity. Our ﬁndings show that arginine methylation of CNBP in
the RG motif did not change the subcellular localization, but regulated its RNA binding activity.
Structured summary of protein interactions:
PRMT1 binds to CNBP by pull down (View interaction)
PRMT1 methylates CNBP by enzymatic study (View interaction)
CNBP physically interacts with PRMT1 by anti tag coimmunoprecipitation (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The 19-kD cellular nucleic acid binding protein (CNBP), also
named ZNF9 (zinc ﬁnger 9), contains seven highly conserved tan-
dem Cys-Cys-His-Cys (CCHC) type zinc knuckle domains (C-u-C-
G-X3-H-X4-C, whereu is an aromatic amino acid and X is a variable
amino acid) [1]. CNBP exhibits sequence similarity to retroviral nu-
cleic acid binding proteins (NBPs) and was thus designated. It has
been reported to be a single-stranded DNA binding protein to the
sterol responsive element in the promoter of genes in cholesterol
biosynthesis pathways [2] and to be involved in the regulation of
the c-myc oncogene [3] and the expression of the human myosin
heavy chain [4]. Cytoplasmic localization of CNBP and its RNA-
binding activity are also reported. For example, CNBP is a key
translation regulator of 50-terminal oligopyrimidine element
(TOP)-containing mRNAs encoding ribosomal proteins and othercomponents of the translational machinery [5]. It is also present
in the ITAF complex promoting cap-independent translation [6].
It binds to G-rich single-stranded nucleic acid and may function
as a nucleic acid chaperone [7]. CNBP is highly conserved among
human, mouse, rat, chicken, Xenopus species and ﬁsh [8]. The dis-
ruption of CNBP caused severe forebrain truncation and defective
neural crest development [9–11].
The expansion of the (CCTG)n repeats in intron 1 of the Cnbp
gene is highly connected to a multi-systemic skeletal muscle dis-
ease myotonic dystrophy type 2 (DM2) [12]. The disease pathogen-
esis mostly likely involves an RNA gain-of-function mechanism by
accumulation of the CCUG repeat. No signiﬁcant alteration in ZNF9
mRNA or protein level was found in myoblast or lymphoblastoid
cell lines from DM2 patients [13,14]. On the other hand, Huichalaf
et al. showed that the protein level of CNBP and 50-TOP RNA bind-
ing activity was reduced in the cytoplasm of DM2 myoblasts. CNBP
inhibition by siRNA in normal cells leads to reduced expression of
RPS17 and eEF1A, suggesting that CNBP supports the translation of
the TOP mRNAs at normal conditions [15].
An RG rich sequence (RGG box) is present between the ﬁrst and
the second zinc ﬁnger knuckle of CNBP throughout vertebrates
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binding and nucleic acid chaperone activity [17]. The sequence is
homologous to the typical substrate domain of protein arginine
methyltransferases (PRMTs). PRMTs catalyze the transfer of methyl
groups from AdoMet to the side chain x-guanido nitrogens of argi-
nine residues in protein substrates and can be further divided into
type I and type II, depending on the catalyses of forming asymmet-
ric di-x-N, N-methylarginines (aDMA) or symmetric di-x-N,N0-
methylarginine (sDMA) residues, respectively [18]. Most of the
methylarginines in the modiﬁed proteins appear to be NG-monom-
ethylarginine (MMA) and aDMA in various RNA binding proteins
(RBPs) within the Arg-Gly-Gly (RGG) context [19]. Protein arginine
methylation is involved in various cellular functions such as signal
transduction, protein subcellular localization, RNA processing and
export, transcriptional regulation, protein–protein interactions,
DNA repair and even embryogenesis [20].
Posttranslational modiﬁcation of CNBP has been focused on
phosphorylation at the C-terminal region by protein kinase A.
CNBP phosphorylation promoted the annealing of the CT-elements
of c-myc promoter [21]. Nevertheless, CNBP was reported as a
putative member of the protein complexes immunopuriﬁed with
an sDMA-speciﬁc antibody [22]. Mono and di-methylation of argi-
nines in the RG region was identiﬁed recently by a proteomic study
[23]. However, the importance of arginine methylation of CNBP has
not been reported. In our recent study we showed that CNBP is a
novel antigen for the autoimmune disease systemic lupus erythe-
matosus (SLE) and the recognition of CNBP might be differentiated
by the level of arginine methylation [24]. In this study we provide
direct evidence for arginine methylation of the CNBP protein in the
RG region. We also investigated whether the RG region is involved
in subcellular localization and RNA interaction of CNBP.
2. Materials and methods
2.1. Plasmid construction
The human CNBP cDNA clone (isoform 4) was obtained from
Source BIOScience LifeSciences (Berlin, Germany). The sequences
of the primers used in this study are shown in Table S1. ZNF-9 for-
ward and reverse primers were used to amplify the CNBP coding
regions and the PCR products were cloned in a TA vector. Frag-
ments from BamHI and SalI digestion were cloned into pET28b to
produce (His)6-tagged recombinant CNBP. The CNBP coding se-
quence was subcloned into pFLAG-CMV2 with the 50 NotI and
30BamHI restriction fragment of ampliﬁed products from the pri-
mer set ZNF9-Not-F and ZNF9-BamH-R. To create the GFP fusion,
the CNBP coding region was ampliﬁed with the primer set GFP-
ZNF9-F and GFP-ZNF9-R, digested with Kpn I and BamHI and sub-
cloned in pEGFP. The 33 bp RG region deletion was created by
QuikChange II Site-Directed Mutagenesis Kit (Stratagen) with
the primers (CNBP-DL1F and CNBP-DL1R). RK mutation of R25
and R27 (RK1) was conducted with the primer set CNBP-RK1F
and CNBP-RK1R. RK mutation of R30, R32 and R34 (RK2) was con-
ducted with the primer set CNBP-RK2F and CNBP-RK2R. The RK
mutation was conducted using the mutated RK1 plasmid as the
template and the RK2 primer set for PCR reaction.
2.2. Puriﬁcation of recombinant proteins expressed in bacteria
(His)6-tagged CNBP protein was prepared from Escherichia coli
BL21 (DE3) cells transformed with pET-28b-CNBP. After grown in
LB media to the mid-late log phase at 37 C, the cells were induced
with 1 mM of IPTG for 4 h. The harvested cells were lysed in lysis
buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH
8.0) by sonication. After centrifugation at 12000g for 10 min,
the supernatant was loaded to a Ni–NTA agarose column (Qiagen).Bound (His)6-CNBP were eluted by elution buffer (50 mM NaH2-
PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0) according to the
suggestions of the manufacturer. To prepare methylated CNBP,
pET-28b-CNBP and pGEX-PRMT1 were co-transformed into BL21
(DE3) cells and selected with both ampicillin (50 lg/ml) and kana-
mycin (25 lg/ml).
2.3. In vitro methylation reaction
In vitro methylation reactions were conducted as described previ-
ously [25]. Basically, recombinant CNBP protein (200 ng) was incu-
bated with 1.5 lCi of [methyl-3H]-AdoMet (60 Ci/mmol, Amersham
Pharmacia) and recombinant rat GST-PRMT1 (200 ng) to the ﬁnal vol-
ume of 15 ll in reaction buffer (50 mM sodium phosphate, pH 7.5).
After incubation at 37 C for 60 min, the reaction was terminated by
the addition of SDS sample buffer on ice, and the samples were sub-
jected to SDS–PAGE. The gels were stained with Coomassie Brilliant
blue, destained, and treated with EN3HANCE (Perkin Elmer). The gels
were then dried and exposed to X-ray ﬁlm at 75 C for 3–5 days.
2.4. Cell culture, transfection, cell extract preparation and
immunoprecipitation
HeLa cell culture, AdOx treatment, transfection by Lipofect-
amine (Invitrogen), and transient PRMT1 knock-down using prmt1
siRNA were conducted as described previously [26]. HeLa cell ex-
tracts were prepared as described [27]. Harvested cells were
washed with phosphate buffer saline, resuspended in buffer A
(phosphate buffered saline with 5% glycerol, 1 mM sodium EGTA,
1 mM dithiothreitol, 0.5% Triton X-100 and Complete EDTA-free
protease inhibitor cocktail [Roche]) and lysed by sonication. Pro-
tein concentration of the cell extracts was determined by the
BCA method (Pierce) with bovine serum albumin as the standard.
Immunopuriﬁcation of FLAG-CNBP from transfected HeLa cell ex-
tract with anti-FLAG-M2 afﬁnity gel (Sigma–Aldrich) was con-
ducted as suggested by the manufacturer and described in [26].
2.5. Western blot analyses
Samples containing equal amounts of protein (30 lg) were sepa-
rated by SDS–PAGE and subsequently transferred to nitrocellulose
membranes (Gelman Science). The membranes were blocked in 5–
7% skimmed milk powder in TTBS (10mM Tris–HCl, pH7.5; 100mM
NaCl; 0.1% tween 20) for 30min, incubated with primary antibodies
(1:550 for SYM10, 1:900 for ASYM24, 1:2500 for anti-PRMT1 fromUp-
state and 1:1500 dilution of anti-FLAG from Sigma) for 1 h, washed
three times in TTBS, then incubated with secondary antibody for
1 h. Chemiluminescent detection was performed using the Supersig-
nal kit (Pierce) or VisGlow substrate for HRP (Visual protein, Taiwan).
2.6. Immunoﬂuorescent analyses
Immunoﬂuorescent analyses were conducted as described in
[26]. HeLa cells cultured on cover glasses were ﬁxed, washed and
permeabilized. After blocking with phosphate buffered saline
(PBS) containing 2% BSA, cells were incubated with blocking buffer
containing goat anti-CNBP antibody (Abcam; diluted 1:200) at 4 C
for 16 h. The cells were then washed with PBS containing 0.01% Tri-
tonX-100 (PBS-T), and incubated with anti-goat-FITC antibody
(1:500). Finally, the cells were washed with PBS-T and observed
with a ﬂuorescence microscope (ZEISS AXioskop2).
2.7. RNA afﬁnity chromatography
Biotinylated RNA with the sequence in the 50-UTR of ribosome
protein S17 (RPS17; 50-guuuccucuuuuaccaaggaccccccgccaacau
Fig. 2. Asymmetric and symmetric arginine methylation of CNBP in the RG repeat
region in cellulo. HeLa cells were transfected with FLAG-tagged CNBP or FLAG-
CNBPDRG plasmids. The FLAG-tagged proteins were immunopuriﬁed and then
analyzed by Western blot with ASYM24 (aDMA-speciﬁc antibody) and SYM10
(sDMA speciﬁc antibody). The blot was stripped of the interacted antibodies and re-
probed with anti-FLAG antibodies.
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China). The RNA (5 lmol) was incubated with 100 ll of streptavi-
din–agarose beads (Invitrogen) at 4 C for 30 min in 1 ml of binding
buffer (10 mM HEPES pH 7.0, 200 mM NaCl, 1 mM dithiothreitol,
10 mM MgCl2, 1% triton X-100 and protease inhibitor). The resin
was washed with binding buffer to remove free biotinylated
RNA. HeLa cell extracts or puriﬁed recombinant CNBP protein
was then incubated with the RNA afﬁnity resin in 1 ml of binding
buffer for 30 min at 4 C. After incubation, the resin was washed
with binding buffer and bound proteins were eluted from the resin
with SDS–PAGE sample buffer and subjected to electrophoresis fol-
lowed by Western blot analysis.
3. Results
3.1. Interaction of CNBP and PRMT1 and in vitro methylation of CNBP
According to UniProtKB/Swiss-Prot, at least 6 isoforms/variants
can be identiﬁed for human CNBP (P62633, Fig. S1). While the lin-
ker regions between other ZFs are about 0–5 residues, the linker
region between the ﬁrst and the second ZF are of 30/23 residues
according to different splicing forms. The RG rich sequence com-
poses about half to two thirds of the linker sequence in different
isoforms.
We examined if CNBP might interact with and be arginine
methylated by the predominant type I protein arginine methyl-
transferase PRMT1 in the RG region. PRMT1 co-immunoprecipi-
tated with full-length FLAG-CNBP expressed from HeLa cells
(Fig. 1A), suggesting the interaction between PRTM1 and CNBP.
Interestingly, the interaction does not depend on the RG domain
that is likely to be the major methylation site of CNBP, because
the RG-deleted CNBP interacts with PRMT1 as well. Direct interac-
tion of CNBP and PRMT1 was further demonstrated by a pull-down
experiment. Puriﬁed (His)6-CNBP protein was incubated with
immobilized GST-PRMT1 on the glutathione resins. As shown in
Fig. S2, (His)6-CNBP bound to immobilized GST-PRMT1 but not
GST alone.
To further demonstrate CNBP as a PRMT1 substrate, we per-
formed in vitro methylation by incubating recombinant CNBP with
GST-tagged rat PRMT1. Recombinant PRMT1 catalyzed the methyl-
ation of full-length but not RG-deleted (His)6-CNBP (Fig. 1B). Muta-
tions of the arginines to lysines also blocked the methylation of
CNBP (data not shown). Furthermore, we prepared recombinant
CNBP with the ﬁrst two arginines (R25, 27) mutated to lysinesFig. 1. CNBP interacts with and is modiﬁed by PRMT1. (A) Co-immunoprecipitation of PR
length or RG-deleted) expressed from transfected HeLa cells. The precipitated proteins w
In vitro methylation of CNBP. Recombinant full length, RG deletion, RK1 (R25, R27 to K) o
GST-PRMT1 and [methyl-3H]-AdoMet. Fluorography of the in vitro methylation product
lower band is likely to be truncated CNBP as determined by mass spectrometric analyse(RK1) or the other three arginines (R30, 32 and 34) mutated to ly-
sines (RK2). The ﬁrst two arginine residues (R25 and 27) appear to
be the major methylation sites as mutation of these residues signif-
icantly reduced the methylation level of CNBP, while mutation of
the last 3 residues showed little differences (Fig. 1B).
3.2. CNBP expressed in HeLa cells is arginine methylated
We had shown in our recent publication that FLAG-CNBP pro-
tein expressed in transfected HeLa cells can be detected by a
methylarginine-speciﬁc antibody, and treatment with a methyl-
transferase inhibitor AdOx reduced the methylarginine signalMT1 with CNBP were shown with afﬁnity puriﬁed FLAG-tagged CNBP proteins (full-
ere detected by Western blot analyses with anti-PRMT1 or anti-FLAG antibodies. (B)
r RK2 (R30, 32 and 34 to K) mutated (His)6-CNBP were incubated with recombinant
s was shown. Coomassie blue stain of the gel indicated equal protein loading. The
s.
Fig. 3. Subcellular localization of CNBP is not affected by its arginine methylation status. (A) Localization of endogenous CNBP in HeLa cells treated with AdOx (100 lM) or
prmt1 siRNA (250 pmol) was detected by immunoﬂuorescent analyses (1000 magniﬁcation) with an anti-CNBP antibody. (B) Localization of GFP-fused full-length or RG-
deleted CNBP was observed by ﬂuorescence microscopy (400 magniﬁcation). ‘‘+’’ or ‘‘‘‘ Indicate the treatment of AdOx or not.
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methylarginine residues.
We further transfected HeLa cells with plasmids to express nor-
mal or mutated FLAG-CNBP. Besides the RG region, an RGG se-
quence is present in the 3rd ZF (R72). We thus prepared RG-
deleted and RG-deleted plus R72K proteins. An aDMA-speciﬁc anti-
body ASYM24 recognized full-length but not RG-deleted or RG-de-
leted/R72K FLAG-CNBP puriﬁed from HeLa cells (Fig. 2). Another
sDMA antibody SYM10 also detected full-length but not RG-de-
leted FLAG-CNBP. The results indicate that CNBP protein contains
aDMA as well as sDMA in the RG region.3.3. Arginine methylation does not affect CNBP subcellular localization
Protein arginine methylation controls various cellular activities,
and its effects on nuclear/cytoplasmic shuttling have been reported
repeatedly [28]. We also showed that the modiﬁcation is involved
in the subcellular localization of a methyl-accepting RNA binding
protein SERBP1 [26]. We thus investigated whether arginine meth-
ylation might affect the distribution of CNBP in cells. As shown in
Fig. 3A, endogenous CNBP is widely distributed throughout the cell
and is concentrated in the nucleus of HeLa cells as revealed by
immunoﬂuorescent analyses with an anti-CNBP antibody. The
Fig. 4. Arginine methylation of CNBP inhibits RNA binding. (A) AdOx treated or untreated HeLa cell extracts (250 lg) were incubated with biotin-labeled RPS17 RNA
immobilized on streptavidin beads in the presence or absence of unlabeled RNA (cold RPS17, 25 lmol). Bound proteins were detected by Western blot analyses with anti-
FLAG antibodies. Input indicates 40 lg of HeLa cell extracts directly loaded on the SDS–PAGE. The faint signal around 40 kDa is likely to be the CNBP dimer. (B) Non-
methylated but not arginine methylated recombinant CNBP binds RNA. Methylated (His)6-CNBP (M-CNBP) and unmethylated CNBP (CNBP) prepared from E. coli were
examined by in vitro methylation with GST-PRMT1 and [methyl-3H]-AdoMet as shown in the upper panel. In the lower panel, CNBP proteins (400 ng) bound to streptavidin
beads coated with the biotin-labeled RPS17 RNA were analyzed by Western blot. Unlabeled RPS17 RNAs (25 and 50 lmol) were included in the incubation for competition.
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PRMT1 by siRNA. We further prepared constructs to express GFP-
fused full-length and RG-deleted or RK mutated CNBP to examine
the subcellular localization of CNBP. All GFP-fused CNBP proteins
mainly localize in the nucleus of HeLa cells as observed by ﬂuores-
cence microscopy whether they were treated with AdOx or not
(Fig. 3B). These results suggest that protein arginine methylation
may not affect CNBP subcellular localization.
3.4. Arginine methylation inhibits interaction of CNBP and RNA
We then examined whether arginine methylation might affect
the RNA binding ability of CNBP. We synthesized a biotin-labeled
single stranded RNA with the 50-TOP sequence of ribosomal protein
S17 (RPS17) that has been reported to speciﬁcally bind to human
CNBP [15]. We showed that FLAG-CNBP from AdOx treated but
not untreated cells interacted with the RPS17 RNA. Addition of
competitive unlabeled RNA reduced the binding (Fig. 4A).
Because PRMTs only exist in eukaryotes, recombinant CNBP ex-
pressed in E. coli should not be methylated. Preparation of recom-
binant arginine methylated CNBP protein expressed from E. coli
cells co-transformed with plasmids expressing PRMT1 had been
described in our previous study [24]. We thus prepared arginine
methylated and unmethylated CNBP in this way for the RNA bind-
ing studies. Besides detection with methylarginine-speciﬁc anti-
body in the previous study [24], we conducted in vitro
methylation to examine the extent of the modiﬁcation in methyl-
ated CNBP (M-CNBP) (upper panel of Fig. 4B). The methylation sites
in unmethylated recombinant (His)6-CNBP (CNBP) were empty and
could be intensively modiﬁed by in vitro methylation with radioac-
tive methyl groups. In contrast, M-CNBP could be barely methyl-
ated, indicating that it had been almost fully methylated already.We observed that unmethylated but not methylated CNBP was
pulled down by the streptavidin beads coated with biotin-RPS17
RNA (Fig. 4B, lower panel). The interaction could be speciﬁcally
competed by unlabeled RNA, indicating the speciﬁcity. The results
of the RNA-binding experiments suggest that methylation of CNBP
block its interaction with the 50-TOP RNA.
4. Discussions
Mono- and di-methylation of two arginines in the RG region of
CNBP isoform 2/5 was identiﬁed by a proteomic study [23]. Re-
cently mono- or di-methylation of R27, 30, 32, and 34 in the RG re-
gion and even the arginine residue in the RGG sequence of the 3rd
ZF have been identiﬁed in another mass spectrometry analysis of
protein methylation [29]. We became interested in CNBP methyla-
tion when we identiﬁed CNBP as a novel autoantigen for SLE and
some autosera from the SLE patients differentially recognized
CNBP due to its arginine methylation level [24]. In this study we
further showed that the RG repeat sequence between the ﬁrst
two zinc-knuckles is the methylation site. Deletion or RK mutation
of this region leads to complete loss of arginine methylation in
CNBP. From our in vitro experiments, we further demonstrated
R25 and R28 to be the major methylation sites of CNBP by PRMT1.
However, the RG region was not required for the interaction of
CNBP with PRMT1.
Arginine methylation of CNBP was ﬁrst suggested in a proteo-
mic study of proteins immunoprecipitated by a sDMA-speciﬁc
antibody SYM10 [22]. In this study we showed that that SYM10
as well as an aDMA-speciﬁc antibody can recognize FLAG-tagged
CNBP prepared from untreated but not AdOx-treated HeLa cells.
Thus arginine methylation of CNBP can be both symmetric and
asymmetric. More and more proteins have been reported to
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example, methyl-DNA binding domain (MBD) 2 protein appears
to contain both sDMA and aDMA [30]. Arginine methylation of
MBD2 reduces MBD2-DNA complex formation and impairs the
transcriptional repression of MBD2. Whether the symmetric and
asymmetric methylations are on the same residues and how differ-
ent type of arginine methylation in CNBP might affect each other
require further investigations.
There are reports indicating the effects of arginine methylation
on the subcellular localization of methylaccepting proteins. Such as
we have shown that the modiﬁcation is involved in the regulation
of subcellular localization or shuttling of SERBP1 [26]. From a pro-
teomic study in trypanosomes, a subset of arginine methylated
protein are involved in intracellular trafﬁcking [31], suggesting
that the cellular methylation conditions might regulate the protein
transport machinery in some way. We detected predominant nu-
clear distributions of the endogenous or transfected CNBP proteins
whether HeLa cells were under normal methylation or hypomethy-
lation conditions. Deletion or RK mutations of the RG segment did
not change the localization of CNBP. The results show that arginine
methylation is less likely to affect the subcellular localization of
CNBP.
Recent reports showed that signiﬁcantly decreased CNBP
expression in DM2 muscle cells could be pathogenic besides the
nuclear accumulation of (CCUG)n RNA from expanded intron 1
[13,14]. 50-TOP RNA-binding activity and protein levels of CNBP
are reduced in cytoplasm of DM2 myoblasts and muscle biopsies
from DM2 patients [15]. In this study we performed similar RNA-
binding experiments and showed that CNBP from AdOx treated
but not from untreated HeLa cells interacted with the 50-TOP of
RPS17 RNA. Similarly, unmethylated but not methylated recombi-
nant CNBP showed the interaction with the 50-TOP RNA. Huichalaf
et al. have shown that recombinant CNBP protein expressed in
E. coli without the PRMT system binds to 50-TOP RNA [15]. How-
ever, CNBP proteins from normal myoblasts that should have been
methylated bind to the RPS17 RNA [15]. The discrepancies might
be resulted from factors in different cells that may interfere with
the RNA binding experiments.
In conclusion, this report is the ﬁrst complete description of
arginine methylation in CNBP. We demonstrated analyses of argi-
nine methylation of CNBP, with supports of the modiﬁcation. Even
though arginine methylation cannot affect the subcellular localiza-
tion of CNBP, it can block the 50-TOP RNA binding of CNBP. As the
reduced 50-TOP activity of CNBP appears to contribute to the defec-
tive translation machinery in DM2 cells, the modiﬁcation of CNBP
might be involved in the pathogenesis DM2.
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